Jump Financial LLC Decreases Holdings in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)

Jump Financial LLC trimmed its position in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 12.2% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 64,400 shares of the biopharmaceutical company’s stock after selling 8,952 shares during the period. Jump Financial LLC owned about 0.11% of Vanda Pharmaceuticals worth $272,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the company. Bailard Inc. purchased a new position in shares of Vanda Pharmaceuticals during the 4th quarter valued at about $111,000. Mackenzie Financial Corp purchased a new position in Vanda Pharmaceuticals in the 4th quarter worth approximately $46,000. China Universal Asset Management Co. Ltd. increased its stake in Vanda Pharmaceuticals by 352.3% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,658 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 5,186 shares during the period. Raymond James & Associates purchased a new position in Vanda Pharmaceuticals in the 4th quarter worth approximately $42,000. Finally, Profit Investment Management LLC increased its stake in Vanda Pharmaceuticals by 19.0% in the 4th quarter. Profit Investment Management LLC now owns 389,274 shares of the biopharmaceutical company’s stock worth $1,643,000 after purchasing an additional 62,277 shares during the period. 88.14% of the stock is owned by hedge funds and other institutional investors.

Vanda Pharmaceuticals Price Performance

Shares of Vanda Pharmaceuticals stock opened at $5.23 on Monday. The business’s 50 day simple moving average is $4.63 and its two-hundred day simple moving average is $4.17. The stock has a market capitalization of $304.39 million, a P/E ratio of -65.38 and a beta of 0.71. Vanda Pharmaceuticals Inc. has a one year low of $3.30 and a one year high of $6.76.

Analyst Ratings Changes

VNDA has been the topic of a number of analyst reports. StockNews.com cut Vanda Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Monday, April 22nd. TheStreet cut Vanda Pharmaceuticals from a “c-” rating to a “d” rating in a research note on Thursday, February 8th.

Vanda Pharmaceuticals Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.